Neutralizing Monoclonal Antibodies Cross-React with Fusion Proteins Encoded by <Emphasis Type="Italic">129L</Emphasis> of the Ectromelia Virus and <Emphasis Type="Italic">A30L</Emphasis> of the Variola Virus

PCR fragments containing the fusion protein genes 129L of the ectromelia virus (EV) and A30L of the variola virus (VARV) were cloned in pQE32. The expression products, recombinant prA30L and pr129L, were isolated from Escherichia coli cell lysates by metal-chelate affinity chromatography. The recombinant proteins retained the capability of oligomerization, characteristic of their natural analogs. ELISA and immunoblotting were used to test 22 monoclonal antibodies (mAbs) to orthopoxviruses (19 mAbs to EV, 2 mAbs to the vaccinia virus (VACV), and 1 mAb to the cowpox virus (CPXV)) for interaction with prA30L, pr129L, and orthopoxviruses. Twelve species-specific epitopes were found in the EV fusion protein 129L and its recombinant analog. Ten cross-reacting epitopes were found in the EV, CPXV, and VACV fusion proteins. Of these, nine epitopes were present both in prA30L and in the VARV fusion protein. Five mAbs interacting with cross-reacting epitopes were capable of efficient neutralization of VACV; two of these mAbs neutralized VARV. It was demonstrated that there are species-specific epitopes in EV 129L and cross-reacting epitopes in the EV, VARV, CPXV, and VACV fusion proteins, including epitopes that induced synthesis of virus-neutralizing antibodies against VACV and VARV.     

Comparative study of the morphology and antigenic properties of recombinant analogs of a Marburg virus nucleoprotein]

The full-length gene for Marburg virus (MV) nucleoprotein (NP) was cloned in prokaryotic pQE32 under the control of the T5 promoter and in eukaryotic pTM1 under the control of the promoter for T7 RNA polymerase. Recombinant NP was synthesized in Escherichia coli and in human kidney cell line 293 cotransfected with recombinant vaccinia virus vTF7-3 expressing T7 RNA polymerase. On evidence of electron microscopy with immune detection, recombinant NP formed tubules of two types in E. coli and of a single type in cell line 293. ELISA and immunoblotting with polyclonal and monoclonal antibodies revealed common antigenic determinants in recombinant NP and natural MV NP.     

Somatosensory evoked potentials in the sleep-wakefulness cycle in healthy subjects and narcolepsy patients]

Studies of somatosensory evoked potentials (SSEPs) were conducted in various functional states of sleep-alertness cycle (relaxed alertness, 2-nd and delta-stages of slow sleep, rapid sleep) in 7 healthy subjects and 8 patients with polysymptom narcolepsy. Integrated amplitude (IA) was calculated in poststimulus intervals, accordingly to SSEPs division into groups of early (20-80 ms), mean (80-200 ms) and late (200-400 ms) components. It has been shown that in patients with polysymptom narcolepsy IA of all SSEPs components in alertness was lower than in healthy subjects; during sleep higher IA values of earlier components were found in comparison with healthy subjects and lower values--of later negative wave at slow sleep. Psychophysiological interpretation of high amplitude negative shift in the area of late SSEPs components during slow sleep is suggested.     

Study of the antigenic structure of the E1 glycoprotein of the Venezuelan equine encephalomyelitis virus using monoclonal antibodies]

The collection of eight rat and mouse hybridomas secreting the high affinity monoclonal antibodies to glycoprotein E1 of the Venezuelan equine encephalomyelitis has been obtained. The antigenic structure of E1 protein has been studied with the use of these antibodies for the strains Trinidad, TC-83 and 230 of the virus. Antigenic map of glycoprotein E1 based on competition radioimmunoanalysis is proposed. Five sites are mapped including eight epitopes binding monoclonal antibodies. Antibodies to sites E1-1, E1-3 and E1-5 are crossreactive in interaction with the virus of Venezuelan equine encephalomyelitis, while antibodies to site E1-5 interact also with the virus of tick-borne encephalitis. Antibodies to site E1-1 possess the protective effect and lack the neutralizing effect in tissue cultures. Antibodies to all sites of E1 protein are devoid of ability to neutralize the Venezuelan equine encephalitis virus.     

Analysis of antigenic determinant profiles of the Ebola virus VP35 protein N-terminal region using its short recombinant fragments

cDNA of fragments of gene VP35 of the Ebola virus (EV) were expressed in vector pQE30 for the purpose of isolation of recombinant fragments of protein VP35. Five short affinity-purified fragments of the EV VP35 protein were analyzed, by using the methods of IEA and immunoblotting, with polyclonal antiviral sera (PAS) against EV and with hybrid monoclonal antibodies (Mabs) IC6 and 6F7 specific to EV VP35 protein. All fragments of protein VP35 with an intact N-terminal region and removed C-terminal region were found to interact effectively with PAS and with Mabs IC6 and 6F7. Rec86N, the smallest of the above fragments, comprised the initial 86 amino acid residues of the VP35 N-terminal region. A removal of 36 amino acid residues from the N-terminal region of Rec310N, the largest recombinant fragment, resulted in a loss of interaction with Mabs IC6 and 6F7, while the interaction with polyclonal antibodies remained intact. The obtained results show that the initial 86 amino acid residues of the N-terminal region of EV VP35 are of the key importance in forming the antigenic structure of VP35 and that they contain multiple B-cell epitopes. Finally, the initial 36 amino acids of VP35 predetermine the shaping-up of two antigenic determinants for Mabs IC6 and 6F7.     

Oncolytic viruses in the therapy of gliomas

Despite the modern advances in medicine, cure for malignant glioblastomas remains an elusive goal. Both the invasive nature and the location in vital areas of the brain make this type of tumors difficult to treat surgically, while adjuvant therapy fails to bring the expected results. Frequent recurrence and invasiveness of malignant gliomas are due to the resistance of glioma stem cells to conventional radiation therapy and chemotherapy. Technological achievements in constructing recombinant viruses yielded strains with high oncolytic activity toward glial tumors. Many of these strains have passed Phase I clinical studies and proved to be highly safe. Although the approach is obviously promising, the available strains are not efficacious enough to cure the disease and need further improvement. The review summarizes the results reported for the most successful variants of oncolytic viruses that have come down to clinical trials and discusses the prospects of new approaches to viral therapy of malignant gliomas.